loader2
Partner With Us NRI

Procter & Gamble Health Ltd share Price Today

Company details

5,095.95
5,275.00
4,636.55
5,642.85
6M Return 2.26%
1Y Return 2.96%
Mkt Cap.(Cr) 8,656.13
Volume 10,253
Div Yield 1.17%
OI
-
OI Chg %
-
Volume 10,253
NSE

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Revenue beat but margins miss; focus on power brands continues…
About The Stock

    Procter & Gamble Health is a leading pharma cum OTC company with key focus on the vitamins, minerals, supplement (VMS) category. • It has legacy brands in the VMS category like Neurobion, Polybion, Evion (all vitamins), Livogen (iron supplement), Nasivion (nasal decongestant), Seven Seas (vitamin- substitute for malt based health drinks) • The company was earlier known as Merck Ltd and was part of Merck KGaA, Germany. In 2018 it (as a consumer health business) was acquired by P&G

Q3FY23

    Beat on revenue front but margins were a big miss. • Revenue grew 19.8% YoY to ₹ 321 crore • On the operational front, EBITDA grew 15.8 % YoY to ₹ 79.7 crore whereas margins were at 24.8% • PAT came in at ₹ 59.2 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Procter & Gamble Health announced Q3FY24 results:

Financial Highlights:

  • Procter & Gamble Health Limited reported a decrease in sales and profit after tax for the Q3FY24. The total sales for the quarter were Rs 248 crore compared to Rs 316 crore a year ago, marking a downturn. Correspondingly, the Profit After Tax (PAT) also declined by 21% to Rs 46 crore.
  • For the nine-month period ending March 31, 2024, P&G Health's sales were recorded at Rs 852 crore, which exhibited a slight reduction from the previous year's sales of Rs 913 crore.
  • The PAT for the nine-month period stood at 184 crore, experiencing a decrease from the Rs 200 crore reported in the prior year.

Milind Thatte, Managing Director, P&G Health India, said, “The Company’s continued efforts to strengthen our reach and distribution with a transformed go-to-market model reflected in a one-time impact on the quarter’s sales owing to the transition and optimization of trade management and inventory. However, we have seen sales recover in the months of March and April.

We continue to drive operational efficiency and explore innovative solutions to accelerate category growth and demand for our portfolio of trusted, quality healthcare brands. The quarter also witnessed prescription growth and share gain for our doctor detailed products indicating a robust demand, and increased efforts to improve awareness of our self-select products.

We remain confident in our integrated growth strategy of a focused product portfolio where performance drives brand choice, superiority, productivity, constructive disruption, and an agile and accountable organization structure to help drive growth and value creation,”he added.

Result PDF

View Other Company Results

Procter & Gamble Health Ltd shares SWOT Analysis

Strengths (7)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Rising Net Cash Flow and Cash from Operating activity
  • Effectively using its capital to generate profit - RoCE improving in last 2 years

Weakness (3)

  • Degrowth in Revenue and Profit
  • Degrowth in Quarterly Revenue and Profit in Recent Results(YoY)
  • Fall in Quarterly Revenue and Net Profit (YoY)

Opportunity (2)

  • Results Screener: Stocks with upcoming results which are seeing positive shifts in share price
  • RSI indicating price strength

Threats (1)

  • High PE (PE > 40)
Discover More

Resistance and support

R1 5,294.6
R2 5,374.3
R3 5,473.6
Pivot

5,195.27

S1 5,115.5
S2 5,016.2
S3 4,936.5
EMA SMA
5,092.1
4,997.4
4,969.0
4,965.6
5,092.3
4,936.6
4,909.1
5,012.9
Delivery and volume
Discover More
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-10-03 4106.95 44711 NSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-10-03 4106.95 6405 NSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 2022-10-03 4106.95 44711 NSE
Discover More
Name Category Shares
PROCTER AND GAMBLE OVERSEAS INDIA B.V. PROMOTER 51.82%

OUR RESEARCH VIEW

Investment recommendation
Revenue beat but margins miss; focus on power brands continues…
Call Date
16 May 2023
Entry Price 4,735.00
Target Price 5,620.00
Duration
12-18 Month
BUY View Report
DISCOVER MORE

FINANCIALS

Sales
Operating Profit
Profit after Tax
DISCOVER MORE
Equity
Reserves and Surplus
Debt
DISCOVER MORE
Sales
Operating Profit
Profit after Tax
DISCOVER MORE
PE
Debt/Equity
P BV
DISCOVER MORE

Procter & Gamble Health Ltd Stocks COMPARISON

Financials( ₹ in Cr) Procter & Gamble Health Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 5,214.85 1,579.30 1,510.40 4,570.80 1,184.80
% Change 0.74 -1.20 -0.19 -1.43 0.39
Mcap ₹ Cr 8,656.13 378,926.98 121,944.71 121,340.57 119,218.60
Revenue TTM ₹ Cr 1,229.62 48,496.85 15,790.60 7,845.00 19,547.40
Net Profit TTM ₹ Cr 229.47 9,648.44 2,513.47 1,600.00 3,854.40
PE TTM 40.74 37.93 28.66 75.74 30.89
1 Year Return 2.96 51.13 48.56 25.57 103.71
ROCE 43.16 17.20 14.76 16.41 23.94
ROE 33.56 16.13 10.66 12.15 20.64
DISCOVER MORE
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 750.89 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 21,424.68 50,451.86
LAST 3M 100,072.29 51,097.20
LAST 6M 183,053.48 43,859.44
LAST 12M 309,832.68 84,987.81

Procter & Gamble Health Ltd Information

Stock PE (TTM)
40.74
Promoter Holding
51.82%
Book Value
485.4699
ROCE
43.16%
ROE
33.56%
Description

  • Proctor & Gamble Health Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 8,936.24 crores, it was incorporated in the year 1967. It has reported consolidated sales of Rs. 22,239.0 crores in March’2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500126 and is listed on the National Stock Exchange (NSE) with the code PGHL.

    Proctor & Gamble Health Ltd, originally incorporated under the name Merck Ltd, is involved in manufacturing and supplying pharmaceuticals and chemicals. The company's pharmaceuticals division is involved in producing prescription drugs, biotechnology products, and consumer health products. At the same time, the chemicals division is involved in supplying pharmaceutical chemicals, formulated chemical products, industrial chemicals, and other chemical products. Proctor & Gamble completed the acquisition of Merck Ltd in December’2018. Its manufacturing facility is established in Goa. Proctor & Gamble Health Ltd, in pursuing the Corporate Social Responsibility requirements, have introduced various health and education schemes aimed at underprivileged children and women of the country. The promoters of the company own 51.82% of the stake in the company, Foreign Institutional Investors (FII) own 6.45%, Domestic Institutional Investors (DII) own 11.81% stake in the company, and others (such as public & retail investors) hold the balance of 29.92%.

    In March 2021, quarterly net revenue was Rs. 219.15 crores, which has decreased marginally by approximately 3.93 % from Rs. 228.11 crores for the January-March 2020 quarter. The quarterly net profit in March 2021 was Rs. 15.17 crores, which has reduced and decreased by nearly 67.35% from a net profit of Rs. 46.46 crores in March 2020. In March 2021, the reported operating profit was at Rs. 138.29 crores, which is also decreased by 19.76% as compared to an operating profit of Rs. 172.34 crores for the quarter ending in March 2020. From an EPS of Rs. 28 in March 2020, the EPS of Proctor & Gamble Health Ltd has reduced and reached Rs. 9.5 per share in March 2021. PGHL's stock closed at Rs. 5,383.60 on 20th August’2021 (NSE) and has given a negative return of 23.78% in the last six months and an annual return of 14.67% in the previous year.

Read More
Registered Address

Godrej One 8th Floor, Projshanagar Vikhroli (East), Mumbai, Maharashtra, 400079

Tel : 91-22-62109000
Email : investorgrievance.im:pg.com
Website : http://www.pghealthindia.com
Registrar

Sharepro Services India P Ltd

AGM Date (Month) : Nov
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500126
NSE Code : PGHL
Book Closure Date (Month) : Nov
BSE Group : A
ISIN : INE199A01012

FAQ’s on Procter & Gamble Health Ltd Shares

You can buy Procter & Gamble Health Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Procter & Gamble Health Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 16, 2024 03:47 PM the closing price of Procter & Gamble Health Ltd was Rs.5,214.85.

The latest PE ratio of Procter & Gamble Health Ltd as of Jul 16, 2024 03:47 PM is 40.74

The latest PB ratio of Procter & Gamble Health Ltd as of Jul 16, 2024 03:47 PM is 0.09

The 52-week high of Procter & Gamble Health Ltd share price is Rs. 5,642.85 while the 52-week low is Rs. 4,636.55

According to analyst recommendations, Procter & Gamble Health Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 16, 2024 03:47 PM, the market cap of Procter & Gamble Health Ltd stood at Rs. 8,656.13 Cr.

Download App

Download Our App

Play Store App Store
market app